BiotechTube
Sensorium Therapeutics

Sensorium Therapeutics

Boston, United States· Est.
sensorium.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Sensorium Therapeutics is a Boston-based, private biotech founded in 2021, operating in the psychedelics and broader CNS therapeutic sector. The company's core asset is the SensAI™ knowledge graph platform, which integrates over 50 million relationships across natural compounds, human experience, pharmacology, and neuroscience to derisk and accelerate drug discovery. This platform has generated a pipeline of three programs in under three years, led by SENS-01, a first-in-class serotonin modulator currently in Phase 1 trials for social anxiety disorder, with additional programs targeting drug-resistant epilepsy and Alzheimer's-related cognitive impairment.

AnxietyEpilepsyAlzheimer's

Technology Platform

SensAI™ knowledge graph platform integrating AI, chemistry, and neuroscience to mine over 50 million relationships across natural compounds, human experience, pharmacology, and clinical data to identify novel therapeutic patterns and derisk CNS drug discovery.

Funding History

2
Total raised:$60M
Series A$30M
Seed$30M

Opportunities

Sensorium has the opportunity to disrupt large, underserved CNS markets like anxiety and epilepsy with novel, naturally-derived compounds that offer improved safety and efficacy profiles.
Its SensAI platform provides a scalable engine for continued pipeline generation, creating long-term value.
Successful Phase 1 data for SENS-01 could attract significant partnership interest or position the company for a premium financing round or eventual IPO.

Risk Factors

The company faces high clinical risk as its lead asset is only in Phase 1, and failure would significantly impact valuation.
The SensAI platform's value is unproven until it yields a clinically successful drug.
As a pre-revenue private company, Sensorium is dependent on volatile venture capital markets for funding to reach its next milestones.

Competitive Landscape

Sensorium competes in the crowded and challenging CNS therapeutic space, facing large pharmaceutical companies and other biotechs developing novel anxiolytics, anti-epileptics, and Alzheimer's treatments. Its differentiation lies in its unique data-driven platform focused on natural compounds, aiming to discover novel mechanisms that have been overlooked by traditional screening methods.

More companies in United States →